Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Dec;49(12):4989-92.
doi: 10.1128/AAC.49.12.4989-4992.2005.

Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata

Affiliations
Comparative Study

Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata

Francesco Barchiesi et al. Antimicrob Agents Chemother. 2005 Dec.

Abstract

We investigated the fungicidal activity of caspofungin (CAS) and amphotericin B (AMB) against 16 clinical isolates of Candida glabrata. The minimum fungicidal concentrations (MFCs) of CAS were similar to those of AMB, ranging from 2.0 to >8.0 microg/ml. Time-kill assays performed on selected isolates showed that AMB was fungicidal at concentrations four times the MIC while CAS was not. A neutropenic-mouse model of disseminated infection was utilized to determine the residual fungal kidney burden. While doses as low as 0.3 and 1 mg/kg of body weight/day of CAS and AMB, respectively, were effective at reducing the counts with respect to controls, organ sterilization was reached when both drugs were administered at 5 mg/kg/day. Our study reveals that, similar to AMB, CAS has the potential for a fungicidal effect in vivo against this difficult-to-treat fungal pathogen.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
CAS (white bars) and AMB (black bars) MICs (A) and MFCs (B) of 16 clinical isolates of Candida glabrata.
FIG. 2.
FIG. 2.
Time-kill studies conducted with C. glabrata 4205 and C. glabrata 4293. The solid lines represent a >99.9% growth reduction compared with the initial inoculum size (fungicidal effect). The limit of detection (20 CFU/ml) is represented by the dotted lines. Each data point represents the mean ± standard deviation for three independent experiments.
FIG. 3.
FIG. 3.
Kidney tissue burden of neutropenic CD1 mice. For study no. 1 (A and B), the mice were infected intravenously with 1.2 × 108 CFU/mouse of C. glabrata 4293 and treated daily with CAS at 0.3 or at 1 mg/kg/day (CAS 0.3 and CAS 1) and with AMB at 0.3 or at 1 mg/kg/day (AMB 0.3 and AMB 1). For study no. 2 (C and D), the mice were infected intravenously with 2.6 × 108 CFU/mouse and treated daily with CAS at 3 or 5 mg/kg/day (CAS 3 and CAS 5) and with AMB at 3 or 5 mg/kg/day (AMB 3 and AMB 5). Tissue burden experiments for control mice (C) were performed on days 1, 3, 5, and 7 postinfection. Tissue burden experiments for treated mice were performed on days 3, 5, and 7 postinfection, which corresponded to a total of 2, 4, and 6 days of therapy, respectively. The bars represent the medians. The asterisks at the bottom of panels A, B, C, and D indicate P values of <0.025.

Similar articles

Cited by

References

    1. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332. - PMC - PubMed
    1. Cantón, E., J. Pemán, M. Gobernado, A. Viudes, and A. Espinel-Ingroff. 2004. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48:2477-2482. - PMC - PubMed
    1. Cantón, E., J. Pemán, A. Viudes, G. Quindós, M. Gobernado, and A. Espinel-Ingroff. 2003. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45:203-206. - PubMed
    1. Colombo, A. L., J. Perfect, M. DiNubile, K. Bartizal, M. Motyl, P. Hicks, R. Lupinacci, C. Sable, and N. Kartsonis. 2003. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22:470-474. - PubMed
    1. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457. - PubMed

Publication types

LinkOut - more resources